Healthcare advisory firm Lumanity recently announced its acquisition of Clarion Healthcare, a life sciences consultancy with a 20-year history of providing services to biopharma clients. The financial terms of the transaction were not publicly disclosed.
A portfolio company of Arsenal Capital Partners, Lumanity is led by Chief Executive Officer Jon Williams and employs more than 1,200 experts in offices across North America, the United Kingdom, Europe, and Asia, operating in over 50 countries in partnership with top pharmaceutical companies and more than 100 biotech companies around the world.
Transforming data and information into insights and evidence, the firm helps its clients power successful commercialization efforts while empowering payers, regulators, providers, and patients to make timely data-driven decisions. The company supports launch readiness and commercialization of nearly 100 brands and more than 50 payer submissions across more than 20 countries.
Founded in 2003, Boston-based Clarion builds leaders in the life sciences, collaborating deeply with clients to solve complex business challenges throughout the product and company lifecycle, helping them develop and execute strategies grounded in creativity, collaboration, and insight.
“We look forward to joining forces with Lumanity on our next chapter of growth,” stated Tom Murtagh, co-founder of Clarion. “We believe Lumanity shares a similar mission-oriented culture and commitment to its clients and its employees. Together, we are eager to disrupt standard thinking regarding commercialization choices and build a more sustainable model to deliver true innovation to the healthcare ecosystem.”
Clarion’s experience in product lifecycle across nearly all therapeutic categories has enabled it to partner with clients to solve problems at the asset, portfolio, and enterprise level, helping them evaluate the potential of early-stage assets in disrupted markets, shape products and markets to ensure successful introduction, and grow organizational capabilities to better tackle rapidly changing requirements for value demonstration and new product commercialization.
The combination of companies will create a stronger global presence, as well as scale up operations in the U.S. and Europe to better assist clients in the development and execution of successful commercialization strategies for biopharma customers holding increasingly complex asset portfolios.